Oppenheimer Equities Analysts Lower Earnings Estimates for Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPHGet Rating) (TSE:AUP) – Stock analysts at Oppenheimer dropped their Q2 2022 earnings estimates for shares of Aurinia Pharmaceuticals in a note issued to investors on Tuesday, May 10th. Oppenheimer analyst J. Kim now anticipates that the biotechnology company will post earnings of ($0.22) per share for the quarter, down from their prior forecast of ($0.21). Oppenheimer also issued estimates for Aurinia Pharmaceuticals’ Q3 2022 earnings at ($0.23) EPS, Q4 2022 earnings at ($0.20) EPS, FY2022 earnings at ($0.90) EPS, FY2023 earnings at ($0.40) EPS, FY2024 earnings at $0.16 EPS and FY2025 earnings at $0.62 EPS.

Aurinia Pharmaceuticals (NASDAQ:AUPHGet Rating) (TSE:AUP) last posted its quarterly earnings results on Tuesday, May 10th. The biotechnology company reported ($0.27) earnings per share for the quarter, hitting the consensus estimate of ($0.27). Aurinia Pharmaceuticals had a negative return on equity of 45.48% and a negative net margin of 253.66%. During the same quarter in the prior year, the business posted ($0.40) earnings per share.

A number of other research firms have also weighed in on AUPH. HC Wainwright reduced their price objective on shares of Aurinia Pharmaceuticals from $33.00 to $30.00 in a research note on Wednesday, May 4th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Aurinia Pharmaceuticals in a research note on Thursday, April 28th. StockNews.com began coverage on Aurinia Pharmaceuticals in a research note on Thursday, March 31st. They issued a “sell” rating for the company. SVB Leerink decreased their price target on Aurinia Pharmaceuticals from $30.00 to $22.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 8th. Finally, Zacks Investment Research lowered shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, May 4th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. According to MarketBeat, Aurinia Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $25.60.

AUPH opened at $9.89 on Friday. The firm has a 50-day moving average price of $11.39 and a 200-day moving average price of $17.62. Aurinia Pharmaceuticals has a twelve month low of $8.86 and a twelve month high of $33.97. The company has a market capitalization of $1.40 billion, a price-to-earnings ratio of -7.73 and a beta of 1.09.

A number of institutional investors have recently made changes to their positions in AUPH. VELA Investment Management LLC purchased a new position in shares of Aurinia Pharmaceuticals in the 4th quarter worth about $681,000. Thompson Siegel & Walmsley LLC grew its position in Aurinia Pharmaceuticals by 80.0% during the fourth quarter. Thompson Siegel & Walmsley LLC now owns 18,000 shares of the biotechnology company’s stock valued at $412,000 after acquiring an additional 8,000 shares during the last quarter. Berry Street Capital Management LLP purchased a new position in shares of Aurinia Pharmaceuticals during the third quarter worth approximately $3,320,000. Morgan Stanley lifted its holdings in shares of Aurinia Pharmaceuticals by 85.1% in the 3rd quarter. Morgan Stanley now owns 6,702,366 shares of the biotechnology company’s stock worth $148,323,000 after acquiring an additional 3,080,674 shares during the last quarter. Finally, Tudor Investment Corp Et Al purchased a new stake in shares of Aurinia Pharmaceuticals in the 3rd quarter valued at $354,000. Institutional investors and hedge funds own 33.09% of the company’s stock.

About Aurinia Pharmaceuticals (Get Rating)

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis.

Read More

Earnings History and Estimates for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.